An interventional study of ADT-train in Prostate Cancer, sponsored by The Swedish School of Sport and Health Sciences. Recruiting at 1 site in Sweden. Open to male participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-06-10.
Sponsored by The Swedish School of Sport and Health Sciences · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 153 studies in Prostatic Neoplasms with a site in Sweden — 35 open to participants now, 57 under way, 22 of them phase 3. Prostatic Neoplasms · Sweden.
Among the 153 studies in Prostatic Neoplasms with a site in Sweden, this one is the 114th largest by planned enrollment of the 128 interventional ones that give a count, is one of 13 that started in 2024, is one of 29 with no phase, reaches primary completion later than 18 of the 56 other live ones, and was the 133rd registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →35 of the 153 studies in Prostatic Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Sweden, United States, Australia and 21 more countries
Ages 18+ · Men only
Bayer · Sites in Sweden, Belgium, Finland and 13 more countries
Ages 18+ · Men only
Region Stockholm · Sites in Sweden
Ages 18+ · Men only
AstraZeneca · Sites in Sweden, United States, Argentina and 25 more countries
Ages 18+ · Men only
Merck Sharp & Dohme LLC · Sites in Sweden, United States, Argentina and 32 more countries
Ages 18+ · Men only
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 50 Years to 80 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
153 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 26 · Phase 3 69 · Phase 4 2
First in 1991; this study’s year is marked. 13 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 462 across the 128 interventional studies, 1,472 across the 25 observational. Of the 89 that completed or were terminated, 42 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
92 of 153 have an industry lead sponsor. The 10 most frequent:
The Swedish School of Sport and Health Sciences is the lead sponsor of 12 studies on the registry; 5 are open to participants now.
The Swedish School of Sport and Health Sciences has 1 study filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
15 of the studies in Prostatic Neoplasms with a site in Sweden that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06565247Phase 3Region VästerbottenEvaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation | 2026-12 |
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT06551324Phase 3PfizerA Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | 2027-02-28 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
| NCT05794906Phase 3BayerA Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies | 2027-07-30 |
Add all 15 to your calendar (.ics) → With an account.
Among the 153 studies in Prostatic Neoplasms with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the effects of a newly developed training concept on men with prostate cancer undergoing androgen deprivation therapy (ADT).
The main questions it aims to answer are:
Researchers will compare the new training concept with usual care to evaluate how efficient the training concept is to counteract the ADT-related side effects.
Participants in the intervention group will perform the new training concept twice weekly for 12 weeks. Participants in the control group will only receive usual care. All participants will visit the laboratory at baseline and after 6 and 12 weeks to measure the primary and secondary outcomes.
Detailed description of the training concept applied in the intervention:
The two weekly training sessions will be separated by at least two days and supervised by appropriately trained exercise professionals at The Swedish School of Sport and Health Sciences. The training includes a 10 min warm-up followed by 3-4 sets of 8 maximal repetitions on the flywheel machine followed by 16-24, 20 s intervals on a Monark cycle ergometer. The intervals will be performed as 3 blocks with the intention to execute 8 intervals in each block. When a participant manages to perform all 3 blocks with 8 intervals in each block (a total of 24 intervals) the resistance will be increased by \~20 W. The rest period between the intervals will be set to 10 s and the rest between the blocks to 2 min. The starting workload of the intervals will be individually adjusted to \~115 % of the participant's power output at VO2peak. The total duration of a training session will be 30-40 min (including worm-up).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The participants will exercise twice weekly performing the newly developed training concept including flywheel resistance training followed by aerobic cycling intervals.
Behavioral: ADT-train
The participants will receive usual care only.
A new training concept is tested on men with prostate cancer receiving androgen deprivation therapy
Aerobic fitness
VO2peak (ml/kg/min); incremental ramp test on a cycle ergometer
Time frame: Baseline and after 6 and 12 weeks
Maximal leg strength
Isometric squat test (N) measured on force plates
Time frame: Baseline and after 6 and 12 weeks
Body fat
Assessed by dual-energy x-ray absorptiometry (DEXA) (kg)
Time frame: Baseline and after 6 and 12 weeks
Lean body mass
Assessed by dual-energy x-ray absorptiometry (DEXA) (kg)
Time frame: Baseline and after 6 and 12 weeks
Bone mineral density
Assessed by dual-energy x-ray absorptiometry (DEXA) (g/cm2)
Time frame: Baseline and after 6 and 12 weeks
Quadriceps cross-sectional area
Assessed by ultrasound (mm)
Time frame: Baseline and after 6 and 12 weeks
Static balance
One leg balance test on the right and the left foot. Time to first footing is measured and the number of footings during 60s.
Time frame: Baseline and after 6 and 12 weeks
Walk capacity
Usual and fast pace 6m walk test (s)
Time frame: Baseline and after 6 and 12 weeks
Lower body muscular endurance
30 s chair stand test. Maximal number of sit-to-stand repetitions during 30 s.
Time frame: Baseline and after 6 and 12 weeks
Blood pressure
Assessed by an automated blood pressure monitor (mmHg).
Time frame: Baseline and after 6 and 12 weeks
Whole body glucose uptake
Assessed by an oral glucose tolerance test in which the participants will ingest a standardized glucose drink and blood glucose levels will be monitored throughout a period of 2 hours (mmol/L).
Time frame: Baseline and after 6 and 12 weeks
Whole body insulin response
Assessed by an oral glucose tolerance test in which the participants will ingest a standardized glucose drink and blood insulin levels will be monitored throughout a period of 2 hours (μU/mL).
Time frame: Baseline and after 6 and 12 weeks
Blood biomarkers related to cardiovascular disease.
Assessed by high-multiplex immunoassays quantifying proteins associated with biological functions linked to cardiovascular diseases. Approximately 100 proteins will be assessed. Examples of proteins are: C-Reactive Protein (CRP), Tissue Factor (F3), and Thrombomodulin (THBD).
Time frame: Baseline and after 6 and 12 weeks
Muscle fiber cross-sectional area (CSA)
Type I and type II muscle CSA will be assessed by immunohistochemistry (µm2).
Time frame: Baseline and after 12 weeks
Muscle fiber distribution
Type I and type II muscle fiber distribution will be assessed by immunohistochemistry (%).
Time frame: Baseline and after 12 weeks
Capillary content
The number of capillaries per muscle fiber will be assessed by immunohistochemistry.
Time frame: Baseline and after 12 weeks
Myonuclei content
The number of myonuclei per muscle fiber CSA will be assessed by immunohistochemistry.
Time frame: Baseline and after 12 weeks
Satellite cell content
The number of satellite cells per muscle fiber CSA will be assessed by immunohistochemistry.
Time frame: Baseline and after 12 weeks
Mitochondrial content
Mitochondrial content will be assessed by measuring citrate synthase activity in homogenized muscle samples (mmol/kg/dw/min).
Time frame: Baseline and after 12 weeks
Mitochondrial respiration
Mitochondrial respiration will be assessed by respirometry of permeabilized muscle fibers (respiration ratio).
Time frame: Baseline and after 12 weeks
Genome-wide DNA methylation
Assessed by Illumina EPIC arrays to identify epigenetically regulated genes and pathways associated with exercise and the ADT-treatment.
Time frame: Baseline and after 12 weeks
Transcriptome-wide RNA expression
Assessed by RNA-sequencing to identify differently regulated genes and pathways associated with exercise and the ADT-treatment.
Time frame: Baseline and after 12 weeks
Protein expression
Assessed by Western Blot and ELISA (AU). This could for example be proteins related to genes identified by the genome-wide DNA methylation analysis or transcriptome-wide RNA expression analysis.
Time frame: Baseline and after 12 weeks
Gene expression
Assessed by quantitative real-time PCR (AU). This could for example be genes identified by the genome-wide DNA methylation analysis or transcriptome-wide RNA expression analysis.
Time frame: Baseline and after 12 weeks
Cancer treatment-related symptoms
Assessed by the National Prostate Cancer Register (NPCR) form. Scores scaled from 0 to 7. A higher score indicates more severe symptoms.
Time frame: Baseline and after 6 and 12 weeks
Physical activity
Assessed by the physical activity questionnaire. Scores scaled from 1 to 8. A higher score indicates a more physically active participant.
Time frame: Baseline and after 6 and 12 weeks
Physical and psychological health
Assessed by the Short Form Health Survey (SF-36). Scores scaled from 1 to 6. A higher score indicates better physical and psychological health.
Time frame: Baseline and after 6 and 12 weeks
Anxiety and depression
Assessed by the Hospital Anxiety and Depression Scale (HADS). Scores scaled from 0 to 3. A higher score indicates more anxiety and depression.
Time frame: Baseline and after 6 and 12 weeks
Cancer and treatment-related fatigue
Assessed by the Multidimensional Fatigue Inventory survey (MFI-20). Scores scaled from 1 to 5. A higher score indicates more fatigue.
Time frame: Baseline and after 6 and 12 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.
Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 31 months is below that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Swedish School of Sport and Health Sciences